NeuroBo Pharmaceuticals | S-1: General form for registration of securities under the Securities Act of 1933
NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals, Inc. Posted an Updated Corporate Presentation
NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
NeuroBo Pharmaceuticals | 8-K: Entered into a Securities Purchase Agreement
NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals' Da-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, And Lipid-Lowering Effects Compared to Survodutide, In Pre-Clinical Models
NeuroBo Pharmaceuticals | 8-K: Poll Results of NeuroBo Pharmaceuticals Meeting
NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals’ DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone
NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
NeuroBo Pharmaceuticals | DEF 14A: Definitive information statements
NeuroBo Pharmaceuticals | 8-K: NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June
NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals, Inc. Posted an Updated Corporate Presentation
NeuroBo Pharmaceuticals | S-3: Registration statement for specified transactions by certain issuers
NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer
NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals, Inc. Posted an Updated Corporate Presentation
NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
No Data